Home   >  
Protease/Metabolic Enzyme
  • Protease/Metabolic Enzyme

Classified by application

All Products

Signaling Pathways

Research Areas

Nature products






Raw Materials


Chemical Structure Cat. No. Product Name CAS No.
Olutasidenib Chemical Structure
BCP30919 Olutasidenib 1887014-12-1
Olutasidenib is a potent, selective inhibitor of mutant Isocitrate dehydrogenase (IDH)1 for the treatment of acute myeloid leukemia.
IDH-305 Chemical Structure
BCP30411 IDH-305 1628805-46-8
IDH-305 is an inhibitor of isocitrate dehydrogenase (IDH).
GSK321 Chemical Structure
BCP20143 GSK321 1816331-63-1
GSK321 is a potent and selective IDH1 mutant inhibitor.
BAY-1436032 Chemical Structure
BCP18989 BAY-1436032 1803274-65-8
BAY-1436032 is a novel pan-mutant isocitrate dehydrogenase 1 (IDH1) inhibitor.
Mutant IDH1-IN-1 Chemical Structure
BCP13615 Mutant IDH1-IN-1 1355326-21-4
Mutant IDH1-IN-1 is a potent mutant IDH1 R132H inhibitor with IC50 < 0.1 uM(A level in Patent); more bioactivity information in Patent WO2012009678A1.
Mutant IDH1 inhibitor Chemical Structure
BCP16459 Mutant IDH1 inhibitor 1429180-08-4
Mutant IDH1 Inhibitor is a potent mutant IDH1 R132H inhibitor with IC50 of < 72 nM.
Mutant IDH1-IN-2 Chemical Structure
BCP16464 Mutant IDH1-IN-2 1429176-69-1
Mutant IDH1-IN-2 is a inhibitor of mutant Isocitrate dehydrogenase (IDH) proteins, with IC50 of in LS-MS biochemical assay, IC50 of 16.6 nM in Fluorescence biochemical assay.
AGI6780 Chemical Structure
BCP07383 AGI6780 1432660-47-3
AGI-6780 is the first highly potent and selective small molecule inhibitor of isocitrate dehydrogenases, which binds in an allosteric manner at the dimer interface of mutant IDH2-R140Q.
AGI-5198 Chemical Structure
BCP07382 AGI-5198 1355326-35-0
AGI-5198, a novel R132H-IDH1 inhibitor, identified through a high-throughput screen blocked, in a dose-dependent manner, the ability of the mutant enzyme (mIDH1) to produce R-2-hydroxyglutarate (R-2HG).
Ivosidenib Chemical Structure
BCP15362 Ivosidenib 1448347-49-6
Ivosidenib is an orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1), with potential antineoplastic activity. Ivosidenib specifically inhibits a mutated form of IDH1 in the cytoplasm, which inhibits the formation of the oncometabolite, 2-hydroxyglutarate (2HG). This may lead to both an induction of cellular differentiation and an inhibition of cellular proliferation in IDH1-expressing tumor cells.
12下一页共 15 条记录 1 / 2 页